

# Participatory Mathematical Modeling Approach for Policymaking during the First Year of the COVID-19 Crisis, Jordan

## Appendix

### Model Description

Our participatory modeling approach used the COVID-19 International Modeling Consortium (CoMo) model (V17.20) (1). The model has been actively developed throughout the COVID19 pandemic by a global consortium of scientists including members of the EMRO modeling support team. The code is open source and publicly available. The version of the model used in this analysis (version 17.2) is available at <https://github.com/ocelhay/como/releases/tag/v17.2.0>.

The CoMo model is an age-dependent, deterministic, SEIR (Susceptible - Exposed - Infectious – Recovered) compartmental model that models transmission of SARS-CoV-2 in the population and can be used to investigate the relative impact of a variety of PHSM. The model considers five levels of infection severity: asymptomatic, symptomatic, infections requiring hospitalization, intensive care treatment, and ventilated intensive care treatment. Infection severity and associated mortality are age-dependent, in that the proportion of infected individuals requiring hospitalization, and the proportion that die, varies with age. In addition to predicting case and death rates at various time points, the CoMo model also incorporates two sub-models: hospital and critical care requirements and implementation of public health and safety measures. The CoMo model incorporates a hospital sub-model that suggests when hospital and critical care requirements will exceed the capacity of the country's healthcare system, including treatment in hospital beds, ICUs, and ventilators.

The CoMo model also incorporates an explicit representation of various PHSM to mitigate the spread of SARS CoV-2. These measures are: self-isolation of symptomatic individuals and self-quarantine of members of their household, screening of the contacts of individuals with a positive diagnostic test result, mass testing, school closure, workplace closure, physical distancing measures, border closure, shielding elderly individuals, handwashing, and mask-wearing. For each PHSM, users can vary the timing and duration, as well as the coverage, defined as the proportion of the population that adheres to the intervention, and adherence, defined as the proportion of time in a given day that an average individual adheres to the intervention. The coverage and adherence values act on the age- and location-dependent contact matrices (2). Coverage values of each PHSM in the model may vary over time to simulate interventions being relaxed and reinstated according to policy mandates.

## Model Equations

This Supplemental Material provides an outline of the equations and parameters describing the CoMo model (1). The CoMo model is written in R and deployed via a Shiny App (comomodel.net). Equations in this document are based upon the solver in v16.6.0 of the comoOdeCpp R package, which is paired with v17.2 of the CoMo model. This combination of model and solver were used in the analyses. An R script of the solver (for use with the deSolve package) is available in the tests folder of the comoOdeCpp package.

Notation in this document aims to stay consistent with 1) the code in the solver, 2) the model equations in the original paper of Aguas et al. (1) (which were not published for v17.2 of the model), 3) the code in R for use with the deSolve package. A few adjustments have been made for consistency across the notation (e.g., durations all use the same symbol).

### Differential equations

For clarity and consistency, derivatives have been written in the following form:

derivative = ...

transmission terms

+ disease processes

+ quarantine

+ aging

+ natural mortality

+ births

Susceptible individuals

$$\frac{dS}{dt} = -S\lambda - vAS + \omega R + v_d V - q_r S + 1/v_q QS + A_{age}S - \mu S + b$$

Susceptible individuals, currently quarantining

$$\frac{dQS}{dt} = -\lambda_q QS + q_r S - 1/v_q QS + A_{age}QS - \mu QS$$

Infected and incubating

$$\frac{dE}{dt} = S\lambda - \gamma E - vAE - q_r E + 1/v_q QE + A_{age}E - \mu E$$

Infected and incubating, currently quarantining

$$\frac{dQE}{dt} = \lambda_q QS - \gamma QE + q_r E - 1/v_q QE + A_{age}QE - \mu QE$$

Infectious symptomatic individuals

$$\frac{dI}{dt} = \dots$$

$$\begin{aligned} & \gamma(1 - p_{clin})(1 - s_{screen})(1 - p_{ihr})(1 - A_u u_E)E \dots \\ & + \gamma(1 - p_{clinV})(1 - s_{screen})(1 - \sigma_{EV} p_{ihr})(1 - A_u u_{EV})EV \dots \\ & + \gamma(1 - p_{clinVR})(1 - s_{screen})(1 - \sigma_{EVR} p_{ihr})(1 - A_u u_{EVR})EVR \dots \\ & + \gamma(1 - p_{clinR})(1 - s_{screen})(1 - \sigma_{ER} p_{ihr})(1 - A_u u_{ER})ER \dots \\ & - vA_v I - v_i I - u_I A_u I \dots \\ & - q_r I + 1/v_q QI + A_{age}I - \mu I \end{aligned}$$

Infectious individuals (currently quarantining)

$$\begin{aligned} \frac{dQI}{dt} &= \gamma(1 - p_{ihr})(1 - p_{clin})QE \dots \\ & + \gamma(1 - \sigma_{EV} p_{ihr})(1 - p_{clinV})QEV \dots \end{aligned}$$

$$\begin{aligned}
& +\gamma(1 - \sigma_{EVR}p_{ihr})(1 - p_{clinVR})QEVR... \\
& +\gamma(1 - \sigma_{ER}p_{ihr})(1 - p_{clinR})QER... \\
& -v_i QI + q_r I - 1/v_q QI + A_{age} QI - \mu QI
\end{aligned}$$

Symptomatic and reported cases

$$\begin{aligned}
\frac{dCL}{dt} = & \gamma p_{clin}(1 - A_u u_E)(1 - c_{iso})(1 - p_{ihr})(1 - q_r)E... \\
& +\gamma p_{clinV}(1 - A_u u_{EV})(1 - c_{iso})(1 - \sigma_{EV}p_{ihr})(1 - q_r)EV... \\
& +\gamma p_{clinVR}(1 - A_u u_{EVR})(1 - c_{iso})(1 - \sigma_{EVR}p_{ihr})(1 - q_r)EVR... \\
& +\gamma p_{clinR}(1 - A_u u_{ER})(1 - c_{iso})(1 - \sigma_{ER}p_{ihr})(1 - q_r)ER... \\
& -u_{CL} A_u CL - v_i CL + 1/v_q QC + A_{age} CL - \mu CL
\end{aligned}$$

$$\frac{dQC}{dt} = \dots$$

$$\begin{aligned}
& \gamma p_{clin}(1 - c_{iso})(1 - A_u u_E)(1 - p_{ihr})q_r E... \\
& +\gamma p_{clinV}(1 - c_{iso})(1 - A_u u_{EV})(1 - \sigma_{EV}p_{ihr})q_r EV... \\
& +\gamma p_{clinVR}(1 - c_{iso})(1 - A_u u_{EVR})(1 - \sigma_{EVR}p_{ihr})q_r EVR... \\
& +\gamma p_{clinR}(1 - c_{iso})(1 - A_u u_{ER})(1 - \sigma_{ER}p_{ihr})q_r ER... \\
& +\gamma(1 - p_{ihr})p_{clin}QE... \\
& +\gamma(1 - \sigma_{EV}p_{ihr})p_{clinV}QEV... \\
& +\gamma(1 - \sigma_{EVR}p_{ihr})p_{clinVR}QEVR... \\
& +\gamma(1 - \sigma_{ER}p_{ihr})p_{clinR}QER... \\
& -v_i QC - 1/v_q QC + A_{age} QC - \mu QC
\end{aligned}$$

Self-isolating

$$\frac{dX}{dt} = \dots$$

$$\gamma c_{iso}(1 - A_u u_E)p_{clin}(1 - p_{ihr})E...$$

$$\begin{aligned}
& +\gamma S_{screen}(1 - A_u u_E)(1 - p_{clin})(1 - p_{ihr})E... \\
& \quad +\gamma C_{iso}(1 - A_u u_{EV})p_{clinV}(1 - p_{ihr})EV... \\
& +\gamma S_{screen}(1 - A_u u_{EV})(1 - p_{clinV})(1 - p_{ihr})EV... \\
& \quad +\gamma C_{iso}(1 - A_u u_{EVR})p_{clinVR}(1 - p_{ihr})EVR... \\
& +\gamma S_{screen}(1 - A_u u_{EVR})(1 - p_{clinVR})(1 - p_{ihr})EVR... \\
& \quad +\gamma C_{iso}(1 - A_u u_{ER})p_{clinR}(1 - p_{ihr})ER... \\
& +\gamma S_{screen}(1 - A_u u_{ER})(1 - p_{clinR})(1 - p_{ihr})ER... \\
& \quad -v_i X + A_{age}X - \mu X
\end{aligned}$$

Quarantined due to testing

$$\begin{aligned}
& \frac{dZ}{dt} = ... \\
& \quad \gamma u_E A_u (1 - p_{ihr})E... \\
& \quad +\gamma u_{EV} A_u (1 - p_{ihr})EV... \\
& \quad +\gamma u_{EVR} A_u (1 - p_{ihr})EVR... \\
& \quad +\gamma u_{ER} A_u (1 - p_{ihr})ER... \\
& +u_I A_u I + u_{CL} A_u CL + u_{HC} A_u HC + u_{HCICU} A_u HCICU + u_{HCV} A_u HCV... \\
& \quad -1/v_{iso} Z - \mu Z
\end{aligned}$$

Recovered and immune individuals

$$\begin{aligned}
\frac{dR}{dt} = & -\lambda \sigma_R R + v_i I + v_i X + v_i CL - \omega R + ... \\
& v_H p_{O2} (1 - d_{O2} \delta_{HO2}) p_{ifr} H + ... \\
& v_H (1 - p_{O2}) (1 - \delta_H) p_{ifr} H + ... \\
& v_{HC} p_{O2} (1 - \delta_{HC02}) p_{ifr} HC + ... \\
& v_{HC} (1 - p_{O2}) (1 - \delta_{HC}) p_{ifr} HC + ...
\end{aligned}$$

$$\begin{aligned}
& v_{ICU}p_{O_2} (1 - d_{O_2}\delta_{ICUO_2})p_{ifr}ICU + \dots \\
& v_{ICU}(1 - p_{O_2}) (1 - \delta_{ICU})p_{ifr}ICU + \dots \\
& v_{ICUC}p_{O_2} (1 - d_{O_2C}\delta_{ICUCO_2})p_{ifr}ICUC + \dots \\
& v_{ICUC}(1 - p_{O_2}) (1 - \delta_{ICUC})p_{ifr}ICUC + \dots \\
& v_{VENT}(1 - d_{VENT}\delta_{VENT})p_{ifr}VENT + \dots \\
& v_{VENTC}(1 - d_{VENTC}\delta_{VENTC})p_{ifr}VENTC + \dots \\
& v_{VENTC}(1 - d_{VENTC}\delta_{VENTC})p_{ifr}ICUCV + \dots \\
& v_{HC}p_{O_2}(1 - \delta_{HCICUO_2})p_{ifr}HCICU + \dots \\
& v_{HC}(1 - p_{O_2})(1 - \delta_{HCICU})p_{ifr}HCICU + \dots \\
& v_{VENTC}(1 - \delta_{HCVENT})p_{ifr}HCV + \dots \\
& v_{dr}VR - v_{AR} + 1/v_{iso}Z - q_rR + 1/q_rQR + A_{age}R - \mu R
\end{aligned}$$

Previously infected individuals, currently quarantining

$$\frac{dQR}{dt} = v_iQI + v_iQC + v_{dr}QVR + q_rR - 1/v_qQR + A_{age}QR - \mu QR$$

Infected and incubating, from previously vaccinated individuals

$$\frac{dEV}{dt} = (1 - p_v) * \lambda V - \gamma EV - q_rEV + 1/v_qQEV + A_{age}EV - \mu EV$$

Infected and incubating, from previously vaccinated individuals, currently quarantining

$$\frac{dQEV}{dt} = (1 - p_v) * \lambda_qQV - \gamma QEV + q_rEV - 1/v_qQEV + A_{age}QEV - \mu QEV$$

Infected and incubating, from previously infected

$$\frac{dER}{dt} = \lambda \sigma_R R - \gamma ER - q_rER + 1/v_qQER + A_{age}ER - \mu ER$$

Infected and incubating, from previously infected, currently quarantining

$$\frac{dQER}{dt} = \lambda_q \sigma_R QR - \gamma QER + q_rER - 1/v_qQER + A_{age}QER - \mu QER$$

Vaccinated individuals from susceptible

$$\frac{dV}{dt} = vAS - (1 - p_V) * \lambda V + \omega VR - v_d V - q_r V + A_{age} V - \mu V$$

Vaccinated individuals from susceptible, currently quarantining

$$\frac{dQV}{dt} = - (1 - p_V) * \lambda_q QV + \omega QVR + q_r V - 1/v_q QV + A_{age} QV - \mu QV$$

Vaccinated individuals (after being previously infected, recovered)

$$\frac{dVR}{dt} = vAE + vAI + vAR - (1 - p_{VR}) * \lambda VR - v_{dr} VR - \omega VR - q_r VR + 1/v_q QVR + A_{age} VR - \mu VR$$

Vaccinated individuals (after being previously infected, recovered) (currently quarantining)

$$\frac{dQVR}{dt} = - (1 - p_{VR}) * \lambda QVR - v_{dr} QVR - \omega QVR + q_r VR + A_{age} QVR - \mu QVR$$

Infected and incubating, from previously infected and vaccinated

$$\frac{dEVR}{dt} = (1 - p_{VR}) * \lambda VR - \gamma EVR - q_r EVR + 1/v_q QEVR + A_{age} EVR - \mu EVR$$

Infected and incubating, from previously infected and vaccinated (currently quarantining)

$$\frac{dQEVR}{dt} = (1 - p_{VR}) * \lambda_q QVR - \gamma QEVR + q_r EVR - 1/q_d QEVR + A_{age} QEVR - \mu QEVR$$

States involving hospitalization (or requiring hospitalization)

Hospitalized

$$\frac{dH}{dt} = \dots$$

$$\gamma p_{ihr} (1 - p_{ICU}) (1 - p_{crit}) r_H E \dots$$

$$+ \gamma p_{ihr} (1 - p_{ICU}) (1 - p_{crit}) r_H QE \dots$$

$$+ \gamma p_{ihr} \sigma_{EV} (1 - p_{ICUV}) (1 - p_{critH}) r_H EV \dots$$

$$+ \gamma p_{ihr} \sigma_{ER} (1 - p_{ICUV}) (1 - p_{critH}) r_H QEV \dots$$

$$+ \gamma p_{ihr} \sigma_{EVR} (1 - p_{ICUVR}) (1 - p_{critH}) r_H EVR \dots$$

$$\begin{aligned}
& +\gamma p_{ihr} \sigma_{EVR} (1 - p_{ICUVR}) (1 - p_{critH}) r_H QEVR... \\
& \quad +\gamma p_{ihr} \sigma_{ER} (1 - p_{ICUR}) (1 - p_{critH}) r_H ER... \\
& +\gamma p_{ihr} \sigma_{ER} (1 - p_{ICUR}) (1 - p_{critH}) r_H QER... \\
& \quad - \nu_H H + A_{age} H - \mu H
\end{aligned}$$

Requiring hospitalization, not hospitalized due to capacity

$$\begin{aligned}
& \frac{dHC}{dt} = \dots \\
& \quad +\gamma p_{ihr} (1 - p_{ICU}) (1 - r_H) E \\
& \quad \quad +\gamma p_{ihr} (1 - p_{ICU}) p_{crit} r_H E \\
& +\gamma p_{ihr} (1 - p_{ICU}) (1 - r_H) QE \\
& \quad \quad +\gamma p_{ihr} (1 - p_{ICU}) p_{crit} r_H QE \\
& +\gamma p_{ihr} \sigma_{EV} (1 - p_{ICUV}) (1 - r_H) EV \\
& \quad \quad +\gamma p_{ihr} \sigma_{EV} (1 - p_{ICUV}) p_{crit} r_H EV \\
& +\gamma p_{ihr} \sigma_{EVR} (1 - p_{ICUVR}) (1 - r_H) EVR... \\
& \quad \quad +\gamma p_{ihr} \sigma_{EVR} (1 - p_{ICUVR}) p_{crit} r_H EVR... \\
& +\gamma p_{ihr} \sigma_{ER} (1 - p_{ICUR}) (1 - r_H) ER... \\
& \quad \quad +\gamma p_{ihr} \sigma_{ER} (1 - p_{ICUR}) p_{crit} r_H ER... \\
& +\gamma p_{ihr} \sigma_{EV} (1 - p_{ICUV}) (1 - r_H) QEV... \\
& \quad \quad +\gamma p_{ihr} \sigma_{EV} (1 - p_{ICUV}) p_{crit} r_H QEV... \\
& +\gamma p_{ihr} \sigma_{EVR} (1 - p_{ICUVR}) (1 - r_H) QEVR... \\
& \quad \quad +\gamma p_{ihr} \sigma_{EVR} (1 - p_{ICUVR}) p_{crit} r_H QEVR... \\
& +\gamma p_{ihr} \sigma_{ER} (1 - p_{ICUR}) (1 - r_H) QER... \\
& \quad \quad +\gamma p_{ihr} \sigma_{ER} (1 - p_{ICUR}) p_{crit} r_H QER... \\
& \quad \quad +u_{HC} A_u HC...
\end{aligned}$$

$$-v_{HC}HC + A_{age}HC - \mu HC$$

Severe infection, hospitalized, but placed in surge ward

$$\begin{aligned} \frac{dHCV}{dt} = & \dots \\ & +\gamma(1 - r_{ICU})p_{ihr}p_{ICU}p_{VENTD}E\dots \\ & + \gamma(1 - r_{ICU})p_{ihr}p_{ICU}p_{VENTD}QE\dots \\ & +\gamma(1 - r_{ICU})\sigma_{EV}p_{ihr}p_{ICUV}p_{VENTV}EV\dots \\ & +\gamma(1 - r_{ICU})\sigma_{EV}p_{ihr}p_{ICUV}p_{VENTV}QEV\dots \\ & +\gamma(1 - r_{ICU})\sigma_{EVR}p_{ihr}p_{ICUVR}p_{VENTVR}EVR\dots \\ & +\gamma(1 - r_{ICU})\sigma_{EVR}p_{ihr}p_{ICUVR}p_{VENTVR}QEVR\dots \\ & +\gamma(1 - r_{ICU})\sigma_{ER}p_{ihr}p_{ICUR}p_{VENTR}ER\dots \\ & +\gamma(1 - r_{ICU})\sigma_{ER}p_{ihr}p_{ICUR}p_{VENTR}QER\dots \\ & -u_{HCV}A_uHCV\dots \\ & -v_{VENTC}HCV + A_{age}HCV - \mu HCV \end{aligned}$$

Severe infection, hospitalized, requiring ICU, not but not granted ICU due to capacity

$$\begin{aligned} \frac{dHCICU}{dt} = & \dots \\ & +\gamma p_{ihr}p_{ICU}(1 - r_{ICU})(1 - p_{VENTD})E\dots \\ & +\gamma p_{ihr}p_{ICU}(1 - r_{ICU})(1 - p_{VENTD})QE\dots \\ & +\gamma p_{ihr}\sigma_{EV}p_{ICUV}(1 - r_{ICU})(1 - p_{VENTV})EV\dots \\ & +\gamma p_{ihr}\sigma_{EV}p_{ICUV}(1 - r_{ICU})(1 - p_{VENTV})QEV\dots \\ & +\gamma p_{ihr}\sigma_{EVR}p_{ICUVR}(1 - r_{ICU})(1 - p_{VENTVR})EVR\dots \\ & +\gamma p_{ihr}\sigma_{EVR}p_{ICUVR}(1 - r_{ICU})(1 - p_{VENTVR})QEVR\dots \\ & +\gamma p_{ihr}\sigma_{ER}p_{ICUR}(1 - r_{ICU})(1 - p_{VENTR})ER\dots \\ & +\gamma p_{ihr}\sigma_{ER}p_{ICUR}(1 - r_{ICU})(1 - p_{VENTR})QER\dots \end{aligned}$$

$$\begin{aligned}
& - u_{HCICU} A_u HCICU \dots \\
& - v_{HC} HCICU + A_{age} HCICU - \mu HCICU
\end{aligned}$$

Severe infection, requiring ICU

$$\begin{aligned}
\frac{dICU}{dt} = & \frac{1}{2} (1 - p_{crit}) ICUC + \dots \\
& + \gamma r_{ICU} p_{ihr} p_{ICU} (1 - p_{crit}) (1 - p_{VENTD}) E \dots \\
& + \gamma r_{ICU} p_{ihr} p_{ICU} (1 - p_{crit}) (1 - p_{VENTD}) Q E \dots \\
& + \gamma r_{ICU} \sigma_{EV} p_{ihr} p_{ICUV} (1 - p_{crit}) (1 - p_{VENTV}) EV \dots \\
& + \gamma r_{ICU} \sigma_{EV} p_{ihr} p_{ICUV} (1 - p_{crit}) (1 - p_{VENTV}) QEV \dots \\
& + \gamma r_{ICU} \sigma_{EVR} p_{ihr} p_{ICUVR} (1 - p_{crit}) (1 - p_{VENTVR}) EVR \dots \\
& + \gamma r_{ICU} \sigma_{EVR} p_{ihr} p_{ICUVR} (1 - p_{crit}) (1 - p_{VENTVR}) QEVR \dots \\
& + \gamma r_{ICU} \sigma_{ER} p_{ihr} p_{ICUR} (1 - p_{crit}) (1 - p_{VENTR}) ER \dots \\
& + \gamma r_{ICU} \sigma_{ER} p_{ihr} p_{ICUR} (1 - p_{crit}) (1 - p_{VENTR}) QER \dots \\
& - v_{ICU} ICU + A_{age} ICU - \mu_{ICU}
\end{aligned}$$

Severe infection, requiring ICU but not receiving ICU due to capacity

$$\begin{aligned}
\frac{dICUC}{dt} = & - \frac{1}{2} (1 - p_{crit}) ICUC \dots \\
& + \gamma r_{ICU} p_{ihr} p_{ICU} p_{crit} (1 - p_{VENTD}) E \dots \\
& + \gamma r_{ICU} p_{ihr} p_{ICU} p_{crit} (1 - p_{VENTD}) Q E \dots \\
& + \gamma r_{ICU} \sigma_{EV} p_{ihr} p_{ICUV} p_{crit} (1 - p_{VENTV}) EV \dots \\
& + \gamma r_{ICU} \sigma_{EV} p_{ihr} p_{ICUV} p_{crit} (1 - p_{VENTV}) QEV \dots \\
& + \gamma r_{ICU} \sigma_{EVR} p_{ihr} p_{ICUVR} p_{crit} (1 - p_{VENTVR}) EVR \dots \\
& + \gamma r_{ICU} \sigma_{EVR} p_{ihr} p_{ICUVR} p_{crit} (1 - p_{VENTVR}) QEVR \dots \\
& + \gamma r_{ICU} \sigma_{ER} p_{ihr} p_{ICUR} p_{crit} (1 - p_{VENTR}) ER \dots \\
& + \gamma r_{ICU} \sigma_{ER} p_{ihr} p_{ICUR} p_{crit} (1 - p_{VENTR}) QER \dots
\end{aligned}$$

$$-v_{ICUC}ICUC + A_{age}ICUC - \mu ICUC$$

Severe infection, hospitalized, requiring ventilator but placed in a surge ward

$$\begin{aligned} \frac{dICUCV}{dt} = & -\frac{1}{2}(1 - p_{critV})ICUCV... \\ & +\gamma r_{ICU}p_{ihr}p_{ICU}p_{crit} p_{VENTD}E... \\ & +\gamma r_{ICU}\sigma_{EV}p_{ihr}p_{ICUV}p_{crit} p_{VENTV}EV... \\ & +\gamma r_{ICU}\sigma_{EVR}p_{ihr}p_{ICUVR}p_{crit} p_{VENTVR}EVR... \\ & +\gamma r_{ICU}\sigma_{ER}p_{ihr}p_{ICUR}p_{crit} p_{VENTR}ER... \\ & +\gamma r_{ICU}p_{ihr}p_{ICU}p_{crit} p_{VENTD}QE... \\ & +\gamma r_{ICU}\sigma_{EV}p_{ihr}p_{ICUV}p_{crit} p_{VENTV}QEV... \\ & +\gamma r_{ICU}\sigma_{EVR}p_{ihr}p_{ICUVR}p_{crit} p_{VENTVR}QEVR... \\ & +\gamma r_{ICU}\sigma_{ER}p_{ihr}p_{ICUR}p_{crit} p_{VENTR}QER... \\ & -v_{VENTC}ICUCV + A_{age}ICUCV - \mu ICUCV \end{aligned}$$

Severe infection, hospitalized in ICU on a ventilator

$$\begin{aligned} \frac{dVENT}{dt} = & ... \\ & \frac{1}{2}(1 - p_{critV})VENTC + \frac{1}{2}(1 - p_{critV})ICUCV... \\ & +\gamma r_{ICU}p_{ihr}p_{ICU}(1 - p_{crit})(1 - p_{critV}) p_{VENTD}E... \\ & +\gamma r_{ICU}p_{ihr}p_{ICU}(1 - p_{crit})(1 - p_{critV}) p_{VENTD}QE... \\ & +\gamma r_{ICU}\sigma_{EV}p_{ihr}p_{ICUV}(1 - p_{crit})(1 - p_{critV}) p_{VENTV}EV... \\ & +\gamma r_{ICU}\sigma_{EV}p_{ihr}p_{ICUV}(1 - p_{crit})(1 - p_{critV}) p_{VENTV}QEV... \\ & +\gamma r_{ICU}\sigma_{EVR}p_{ihr}p_{ICUVR}(1 - p_{crit})(1 - p_{critV}) p_{VENTVR}EVR... \\ & +\gamma r_{ICU}\sigma_{EVR}p_{ihr}p_{ICUVR}(1 - p_{crit})(1 - p_{critV}) p_{VENTVR}QEVR... \\ & +\gamma r_{ICU}\sigma_{ER}p_{ihr}p_{ICUR}(1 - p_{crit})(1 - p_{critV}) p_{VENTR}ER... \\ & +\gamma r_{ICU}\sigma_{ER}p_{ihr}p_{ICUR}(1 - p_{crit})(1 - p_{critV}) p_{VENTR}QER... \end{aligned}$$

$$-v_{VENT}VENT + A_{age}VENT - \mu_{VENT}$$

Severe infection, hospitalized in ICU requiring a ventilator but not on one due to capacity

$$\frac{dVENTC}{dt} = \dots$$

$$-\frac{1}{2}(1 - p_{critV})VENTC \dots$$

$$+\gamma r_{ICU} p_{ihr} p_{ICU} (1 - p_{crit}) p_{critV} p_{VENTD} E \dots$$

$$+\gamma r_{ICU} p_{ihr} p_{ICU} (1 - p_{crit}) p_{critV} p_{VENTD} Q E \dots$$

$$+\gamma r_{ICU} \sigma_{EV} p_{ihr} p_{ICUV} (1 - p_{crit}) p_{critV} p_{VENTV} EV \dots$$

$$+\gamma r_{ICU} \sigma_{EV} p_{ihr} p_{ICUV} (1 - p_{crit}) p_{critV} p_{VENTV} QEV \dots$$

$$+\gamma r_{ICU} \sigma_{EVR} p_{ihr} p_{ICUVR} (1 - p_{crit}) p_{critV} p_{VENTVR} EVR \dots$$

$$+\gamma r_{ICU} \sigma_{EVR} p_{ihr} p_{ICUVR} (1 - p_{crit}) p_{critV} p_{VENTVR} QEVR \dots$$

$$+\gamma r_{ICU} \sigma_{ER} p_{ihr} p_{ICUR} (1 - p_{crit}) p_{critV} p_{VENTR} ER \dots$$

$$+\gamma r_{ICU} \sigma_{ER} p_{ihr} p_{ICUR} (1 - p_{crit}) p_{critV} p_{VENTR} QER \dots$$

$$-v_{VENTC}VENTC + A_{age}VENTC - \mu_{VENTC}$$

Force of infection (lambda, lam,  $\lambda$ )

$$\lambda = \left(1 - \max(\text{hand}, \text{mask})\right) p. s. W$$

$$\frac{\rho E + I + CL + m + (1 - s_{iso})(X + HC + HCICU + HCV) + \rho_s(H + ICU + VENT + ICUC + ICUCV + VENTC)}{P} \dots$$

$$+ (1 - \max(\text{hand}, \text{mask})) p. s. (1 - q_{other}) W_{other} \frac{\rho QE + QI + QC + QEV + QEVR + QER}{P}$$

where

$$\text{mask} = \text{maskeff} * \text{maskcov}; \text{hand} = \text{handeff} * \text{handcov}$$

For those under quarantine, this is adjusted in the following manner:

$$\lambda_q = \left(1 - \max(\text{hand}, \text{mask})\right) ps(1 - q_{home}) W_{home}$$

$$\frac{(1 - s_{iso})(X + HHC + \rho QE + QI + QC + QEV + QEVR + QER)}{P} \dots$$

$$+ \left(1 - \max(\text{hand}, \text{mask})\right) ps(1 - q_{other}) W_{other}$$

$$\frac{\rho E + I + CL + m + (1 - s_{iso})(X + HC + HCICU + HCV) + \rho_s(H + ICU + VENT + ICUC + ICUCV + VENTC)}{P}$$

where

$$P = S + E + I + R + X + Z + CL \dots$$

$$+ V + EV + ER + EVR + VR \dots$$

$$+ H + HC + ICU + ICUC + ICUCV + Vent + VentC + HCICU + HCV \dots$$

$$+QS + QE + QI + QR + QC + QEV + QV + QER + QEVR + QVR$$

Quarantine rate ( $q_r$ )

Quarantine rate (for all non-hospitalized compartments that transition into a quarantine state) is calculated in the following manner (see here):

$$q_r = r_q(1 + \exp(-10(\sigma_q/2 - Q)))$$

Proportion of the population in quarantine:

$$Q = (\Sigma QS + \Sigma QE + \Sigma QI + \Sigma QC + \Sigma QR + \Sigma QV + \Sigma QEV + \Sigma QEVR + \Sigma QER + \Sigma QVR)/(\Sigma P)$$

Vaccination rate ( $v$ )

Vaccination rate is calculated in the following manner (see here):

$$v = -\log(1 - v_{cov})/v_c$$

## Model Parameterization

Several pieces of data were used to parameterize the model for simulations of the COVID-19 outbreak in Jordan. Parameters governing population size (of  $\approx 100$  million individuals), demographic age-structure, fertility, and natural mortality were taken from the 2019 UN Revision of World Population Prospects. Contact data were informed using Prem et al. (2) and average household size is 4.7 (Jordan MoH). Parameters governing infection and disease progression follow the literature on SARS-CoV-2 and COVID-19 and are provided in detail in the supplemental data. Parameters governing healthcare capacity were determined via discussions with in-country partners. Jordan country partners specified in the model that all ICUs are with ventilators with the assumption that severe, and critical patients are admitted to the ICU when requiring mechanical ventilation. Other patients receive care in normal hospital beds with or without oxygen supply. We assumed that the maximum number of hospital beds (3894), the maximum number of ICU beds with ventilators (834) during this period. Parameters governing the time course of hospitalized infections were determined via discussions with in-country partners and are specific to Jordan. Because of various travel restrictions imposed by the Jordanian government in 2020, we assumed that there were no imported cases over the modeled period. Waning immunity was not included in this model.

Within the CoMo model framework, model calibration was performed by adjusting the probability of transmission given an infectious contact and the date of introduction of SARS-CoV-2 into the country. These calibrations were performed visually using the CoMo model application. We were justified in performing visual calibrations given the interactive nature of the user platform, the short time frame in which results were required by the Jordanian government, and a focus on the relative impact of different interventions on future transmission rather than absolute numbers of cases or deaths.

Using the calibrated model, we simulated several different scenarios of the implementation of PHSM for Jordan in 2020 from end of October 2020 until end of January 2021. Parameters governing the PHSM scenarios were set according to discussions with the Jordan Ministry of Health as part of our participatory modeling process. We set parameter values to simulate the changing of PHSM in Jordan at various time points throughout 2020.

## Model Inputs

Appendix Tables 3–11 describe the model inputs.

## References

1. Aguas R, White L, Hupert N, Shretta R, Pan-Ngum W, Celhay O, et al.; CoMo Consortium. Modelling the COVID-19 pandemic in context: an international participatory approach. *BMJ Glob Health*. 2020;5:e003126. [PubMed https://doi.org/10.1136/bmjgh-2020-003126](https://doi.org/10.1136/bmjgh-2020-003126)
2. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. *PLOS Comput Biol*. 2017;13:e1005697. [PubMed https://doi.org/10.1371/journal.pcbi.1005697](https://doi.org/10.1371/journal.pcbi.1005697)

**Appendix Table 1.** Variables. There are 31 different variables that make up the population, 35 derivatives returned from the solver (4 for convenience).

Symbol	Definition
S	Susceptible
E	Infected and incubating
I	Infectious and asymptomatic following incubation
R	Recovered and immune
X	Self-isolating
H	Severe infection: hospitalized (Aguas et al., 2020)
HC	Severe infection, requiring hospitalization, not hospitalized due to lack of capacity (Aguas et al., 2020)
HCICU	Severe infection, hospitalized, requiring ICU, not but not granted ICU due to capacity
HCV	Severe infection, hospitalized, but placed in surge ward
ICU	Severe infection, requiring ICU
ICUC	Severe infection, requiring ICU, not hospitalized due to capacity
ICUCV	Severe infection, hospitalized, requiring ventilator but placed in surge ward
Vent	Severe infection, hospitalized in ICU on a ventilator
VentC	Severe infection, hospitalized in ICU requiring a ventilator but not on one
C	Infectious and mildly symptomatic following incubation (not in the total popn count, L416 comoOde.cpp)
CM	(not in the total popn count, L416 comoOde.cpp)
V	Vaccinated (from susceptible)
QS	Susceptible, quarantining
QE	Infected and incubating, quarantining
QI	Infectious and asymptomatic following incubation, quarantining
QR	Recovered and immune, quarantining
CL	Total cases?
Z	Quarantined due to testing
EV	Infected and incubating, from previously vaccinated individuals
ER	Infected and incubating, from previously infected individuals
EVR	Vaccinated (from previously infected), exposed (from ineffective vaccine).
VR	Vaccinated (from previously infected)
QV	Vaccinated (from susceptible), quarantining
QEV	Vaccinated (from susceptible), exposed (from ineffective vaccine), quarantining
QEVr	Previously infected, exposed (from ineffective vaccine), quarantining
QER	Exposed, quarantining, previously infected
QVR	Vaccinated, quarantining, previously infected
Ab	Those with antibody response. Not part of the population, simply calculated in the solver.

**Appendix Table 2.** Parameters

Parameter name (as used in code)	Symbol	Description	Units
<b>Severity-Mortality Parameters</b>			
ifr?	$p_{ifr}$	Age-based relative fatality rate in well-resourced scenario	%
ihr_col2	$p_{ihr}$	Probability of an infection being severe (requiring hospitalization) by age	%
<b>Population parameters</b>			
mu	$\mu$	1/age-dependent non-Covid-19-related death rate	days
B	$b$	1/ age-dependent fertility rate	days
<b>General parameters</b>			
date_range_simul_start	$t_0$	Date range of simulation – START	
date_range_simul_end	$t_T$	Date range of simulation – END	
init	–	Number of exposed people at start date	
pre	–	Proportion of population with partial immunity at the start date	
p	$p_E$	Probability of infection given contact	
report	$p_{ar}$	Percentage of all asymptomatic infections that are reported	%
reportc	$p_{cr}$	Percentage of all symptomatic infections that are reported	%
reporth_g	$p_{gr}$	Percentage of denied hospitalizations that are reported	%
reporth	$r_H$	Percentage of non-severe hospitalizations that are appropriately treated (realized)	%
reporth_ICU	$r_{ICU}$	Percentage of severe hospitalizations that are appropriately treated (realized)	%
report_v	$p_{avr}$	Percentage of all asymptomatic infections in previously vaccinated people that are reported	
report_vr	$p_{avrr}$	Percentage of all asymptomatic infections in previously vaccinated and exposed people that are reported	
report_r	$p_{arr}$	Percentage of all asymptomatic infections in previously infected people that are reported	

Parameter name (as used in code)	Symbol	Description	Units
report_cv	$p_{cvr}$	Percentage of all symptomatic infections in previously vaccinated people that are reported	
report_cvr	$p_{cvrr}$	Percentage of all symptomatic infections in previously vaccinated and exposed people that are reported	
report_cr	$p_{crr}$	Percentage of all symptomatic infections in previously infected people that are reported	
iterations	—	Iterations (1 to 10,000)	
noise	—	Noise (0.01 to 0.2)	
confidence	—	Confidence (5 to 25)	
sample_size	—	Average sample size for seroprevalence	
Country Area parameters			
country_contact	$C$	Country, used for social Contacts Data	
household_size	$h$	Mean Household size	individuals
mean_imports	$m$	Mean number of infectious migrants per day; note that the code includes a 'travel ban efficacy' parameter but assumed set to zero (see here).	individuals
Virus parameters			
rho	$\rho$	relative infectiousness of incubation phase	
gamma	$\gamma$	incubation period	Days
nui	$v_i$	Average duration of symptomatic infection period	Days
phi	$\phi$	Month of peak infectivity of the virus (1, 2, ..., 12)	
amp	$a$	Annual variation in infectivity of the virus	
omega	$\omega$	duration of naturally acquired immunity	Years
pclin	$p_{clin}$	Probability upon infection of developing clinical symptoms	
prob_icu	$p_{ICU}$	Probability upon hospitalization of requiring ICU admission	%
prob_vent	$p_{VENT}$	Probability upon admission to the ICU of requiring a ventilator	%
propo2	$p_{O2}$	Proportion of hospitalized patients needing O2	
pclin_v	$p_{clinV}$	Probability upon infection of developing clinical symptoms if previously vaccinated	
pclin_vr	$p_{clinVR}$	Probability upon infection of developing clinical symptoms if previously vaccinated and exposed	
pclin_r	$p_{clinR}$	Probability upon infection of developing clinical symptoms if previously infected	
prob_icu_v	$p_{ICUV}$	Probability upon hospitalization of requiring ICU admission if previously vaccinated	%
prob_icu_vr	$p_{ICUVR}$	Probability upon hospitalization of requiring ICU admission if previously vaccinated and exposed	%
prob_icu_r	$p_{ICUR}$	Probability upon hospitalization of requiring ICU admission if previously infected	%
prob_v	$p_{VENTD}$	Derived. Probability upon admission to the ICU of requiring a ventilator. Essentially the same as prob_vent, if dexamethsone is being used then this param is prob_vent*vent_dex, else it is prob_vent (see here).	
prob_v_v	$p_{VENTV}$	Probability upon admission to the ICU of requiring a ventilator if previously vaccinated	%
prob_v_vr	$p_{VENTVR}$	Probability upon admission to the ICU of requiring a ventilator if previously vaccinated and exposed	%
prob_v_r	$p_{VENTR}$	Probability upon admission to the ICU of requiring a ventilator if previously infected	%
sigmaR	$\sigma_R$	Probability of infection of people that have recovered from a previous infection	
sigmaEV	$\sigma_{EV}$	Probability of requiring hospitalization if previously vaccinated	
sigmaER	$\sigma_{ER}$	Probability of requiring hospitalization if previously infected	
sigmaEVR	$\sigma_{EVR}$	Probability of requiring hospitalization if previously infected and vaccinated	
seroneg	$seroneg$	Days from seropositive to seronegative	Days
Hospitalization parameters			
beds_available	—	Maximum number of hospital surge beds	beds
icu_beds_available	—	Maximum number of ICU beds without ventilators	beds
ventilators_available	—	Maximum number of ICU beds with ventilators	beds
rhos	$\rho_s$	Relative percentage of regular daily contacts when hospitalized	
ihr_scaling	—	Scaling factor for infection hospitalization rate: (0.1 to 5)	
pdeath_h	$\delta_H$	Probability of dying when hospitalized (not requiring O2)	
pdeath_ho	$\delta_{HO2}$	Probability of dying when hospitalized if requiring O2	
pdeath_hc	$\delta_{HC}$	Probability of dying when denied hospitalization (not requiring O2)	
pdeath_hco	$\delta_{HCO2}$	Probability of dying when denied hospitalization if requiring O2	
pdeath_icu	$\delta_{ICU}$	Probability of dying when admitted to ICU (not requiring O2)	

Parameter name (as used in code)	Symbol	Description	Units
pdeath_icuo	$\delta_{ICUO2}$	Probability of dying when admitted to ICU if requiring O2	
pdeath_icuc	$\delta_{ICUC}$	Probability of dying when admission to ICU denied (not requiring O2)	
pdeath_icuco	$\delta_{ICUCO2}$	Probability of dying when admission to ICU denied if requiring O2	
pdeath_vent	$\delta_{VENT}$	Probability of dying when ventilated	
pdeath_ventc	$\delta_{VENTC}$	Probability of dying when ventilator denied	
pdeath_vent_hc	$\delta_{HCVENT}$	Probability of dying when ventilator required and not going to hospital	
pdeath_icu_hc	$\delta_{HCICU}$	Probability of dying when ICU required (not O2) and not going to hospital	
pdeath_icu_hco	$\delta_{HCICUO2}$	Probability of dying when ICU required (requiring O2) and not going to hospital	
nus	$v_H$	Average duration of hospitalized infection	Days
nusc	$v_{HC}$	Average duration of infection requiring hospitalization but not receiving it due to capacity (assumed same as nus parameter).	Days
nu_icu	$v_{ICU}$	Average duration of ICU infection	Days
nu_icuc	$v_{ICUC}$	Average duration of infection of individual requiring ICU infection but not receiving it due to capacity (assumed same as nu_icu parameter).	Days
nu_vent	$v_{VENT}$	Average duration of ventilated infected.	Days
nu_ventc	$v_{VENTC}$	Average duration of infection requiring ventilation but not receiving it due to capacity (assumed same as nu_vent parameter).	Days
<b>Interventions Parameters</b>			
selfis_eff	$S_{iso}$	Adherence to self-isolation	%
screen_overdispersion	—	Overdispersion: (1, 2, 3, 4 or 5)	
screen_test_sens	$S_{screen}$	Test sensitivity	%
<b>(*Self-isolation) Household Isolation Parameters</b>			
quarantine_days	$v_q$	Days in isolation for average person	Days
quarantine_effort	$e_q$	Days to implement maximum quarantine coverage (1 to 5)	days
quarantine_eff_other	$q_{other}$	Decrease in the number of other contacts when quarantined	%
quarantine_eff_home	$q_{home}$	Increase in the number of contacts at home when quarantined	%
<b>Social Distancing Parameters</b>			
dist_eff	$disteff$	Adherence to social distancing	%
<b>Handwashing Parameters</b>			
hand_eff	$handeff$	Efficacy of handwashing (0%–25%); note that only the maximum of handwashing or mask-wearing (efficacy * coverage) is used in transmission calculations. Coverage of handwashing (proportion of individuals following handwashing guidelines) is denoted with $handcov$ .	%
<b>Mask-wearing Parameters</b>			
mask_eff	$maskeff$	Efficacy of mask wearing (0%–35%); note that only the maximum of handwashing or mask-wearing (efficacy * coverage) is used in transmission calculations. Coverage of mask wearing (proportion of population following mask wearing guidelines) is denoted with $maskcov$ .	%
<b>Working at Home Parameters</b>			
work_eff	$workeff$	Efficacy of working from home	%
w2h	—	Home contacts inflation due to working from home:	%
<b>School Closures Parameters</b>			
s2h	—	Home contacts inflation due to school closure	%
<b>Shielding the Elderly Parameters</b>			
cocoon_eff	—	Efficacy of shielding the elderly	%
age_cocoon	—	Minimum age for elderly shielding (0 to 100)	y.o.
<b>Vaccination Parameters</b>			
vac_campaign	$v_c$	Time to reach target coverage in vaccination campaign (1 to 52)	weeks
vac_dur	$v_d$	1 / duration of vaccine efficacious period	Years
vac_dur_r	$v_{dr}$	1 / duration of vaccine efficacious period if previously infected	Years
vaccine_eff	$p_v$	Vaccine efficacy	
vaccine_eff_r	$p_{VR}$	Vaccine efficacy if previously infected	
<b>Mass Testing Parameters</b>			
mass_test_sens	$S_{mass}$	Sensitivity of mass testing	%
isolation_days	$v_{iso}$	Isolation days	days
<b>Dexamethasone Parameters</b>			
dexo2	$d_{O2}$	Relative risk of dying if needing O2 and taking dexamethasone	%
dexv	$d_{VENT}$	Relative risk of dying if needing ventilation and taking dexamethasone	%
dexo2c	$d_{O2C}$	Relative risk of dying if needing but not receiving O2 and taking dexamethasone	%
dexvc	$d_{VENTC}$	Relative risk of dying if needing but not receiving ventilation and taking dexamethasone	%

Parameter name (as used in code)	Symbol	Description	Units
vent_dex	–	Change in ventilation requirement if given dexamethasone (multiplier on prob_vent). See description of prob_v parameter.	%
Derived parameters			
aging	$A_{age}$	Aging matrix (assuming states are vectors with elements for each age).	
quarantine_rate	$q_T$	Quarantine rate (see below)	
vaccinate	$v$	Vaccination rate	
age_vaccine_vector	$A_v$	Vector of vaccination uptake by age	
lam	$\lambda$	Force of infection including impact of PHSM (lambda)	
lamq	$\lambda_q$	Force of infection including impact of PHSM (lambda) for those under quarantine	
critH	$p_{critH}$	Calculated from splines.	
crit	$p_{crit}$		
critV	$p_{critV}$		
age_testing_vector	$A_u$	Vector of test rates by age	
ratetestE	$u_E$	Testing rate of the E class	
ratetestEV	$u_{EV}$	Testing rate of the EV class	
ratetestEVR	$u_{EVR}$	Testing rate of the EVR class	
ratetestER	$u_{ER}$	Testing rate of the ER class	
ratetestI	$u_I$	Testing rate of the I class	
ratetestC	$u_{CL}$	Testing rate of the CL class	
ratetestHC	$u_{HC}$	Testing rate of the HC class	
ratetestHCICU	$u_{HCICU}$	Testing rate of the HCICU class	
ratetestHCV	$u_{HCV}$	Testing rate of the HCV class	
screen_eff	$s_{screen}$	Efficacy of screening	
seas	$s$	Seasonality factor; $s = 1 + a \cos(2\pi(t - (365.25\phi/12)))/365.25$	
P	$P$	Total population	
selfis_cov	$c_{iso}$	Coverage of self-isolation	
selfis (here)			

**Appendix Table 3. Cases**

Inputs	Value(s)	Input Source
Number of reported COVID19 cases per day	Cases reported between 24/02/2020 and 15/10/2020	Jordan MoH
Daily COVID19 deaths	deaths reported between 14/02/2020 and 15/10/2020	Jordan MoH

**Appendix Table 4. Severity and Mortality**

Age category	Age-based relative fatality rate in well-resourced scenario (%) data source: <a href="https://science.sciencemag.org/content/sci/suppl/2020/05/12/science.abc3517.DC1/abc3517_Salje_SM_rev2.pdf">https://science.sciencemag.org/content/sci/suppl/2020/05/12/science.abc3517.DC1/abc3517_Salje_SM_rev2.pdf</a>	Age-stratum-specific hospitalization (proportion of all (asymptomatic + symptomatic) infections that lead to hospitalization) (%)
0–5 y.o.	0.6	0.1
5–10 y.o.	0.6	0.1
10–15 y.o.	0.6	0.1
15–20 y.o.	0.6	0.1
20–25 y.o.	1.1	0.5
25–30 y.o.	1.1	0.5
30–35 y.o.	1.9	1.1
35–40 y.o.	1.9	1.1
40–45 y.o.	3.3	1.4
45–50 y.o.	3.3	1.4
50–55 y.o.	6.5	2.9
55–60 y.o.	6.5	2.9
60–65 y.o.	12.6	5.8
65–70 y.o.	12.6	5.8
70–75 y.o.	21	9.3
75–80 y.o.	21	9.3
80–85 y.o.	31.6	26.2
85–90 y.o.	31.6	26.2
90–95 y.o.	31.6	26.2
95–100 y.o.	31.6	26.2
100+ y.o.	31.6	26.2

**Appendix Table 5. Population**

Age category	Population Data Source: UN 2019 Revision of World Population Prospects.	Number of births per person (ie 0.5* births per woman) per day Data Source: UN 2019 Revision of World Population Prospects <sup>7</sup> .	Deaths per person per day Data Source: UN 2019 Revision of World Population Prospects <sup>7</sup> .
0–4 y.o.	1058122	0	9.5131E-06
5–9 y.o.	1154441	0	8.927E-07
10–14 y.o.	1139559	0	7.212E-07
15–19 y.o.	1040294	3.33108E-05	1.3306E-06
20–24 y.o.	940151	0.000141126	1.8731E-06
25–29 y.o.	862385	0.000206421	2.0039E-06
30–34 y.o.	777482	0.000183412	2.3882E-06
35–39 y.o.	713126	0.000110293	3.1029E-06
40–44 y.o.	606717	3.27423E-05	4.7969E-06
45–49 y.o.	534628	2.2533E-06	7.8137E-06
50–54 y.o.	433223	0	1.23955E-05
55–59 y.o.	322368	0	1.99431E-05
60–64 y.o.	217239	0	3.30424E-05
65–69 y.o.	149039	0	5.96328E-05
70–74 y.o.	111528	0	0.000103811
75–79 y.o.	79223	0	0.000169096
80–84 y.o.	43119	0	0.000280179
85–89 y.o.	16283	0	0.000437
90–94 y.o.	3741	0	0.000637149
95–99 y.o.	444	0	0.001002645
100+ y.o.	28	0	0.015899091

**Appendix Table 6. Country Area Parameters**

Inputs	Value(s)	Input Source
Social Contacts Data:	Jordan	Prem, K., A.R. Cook, and M. Jit, <i>Projecting social contact matrices in 152 countries using contact surveys and demographic data</i> . PLoS Comput Biol, 2017. 13(9): p. e1005697.
Mean Household size:	4.7 individuals	Jordan MoH
Mean number of infectious migrants per day:	0 individuals	As the travel restrictions were implemented early in the pandemic it was assumed to be 0 if effective isolation of infectious migrants were in place.

**Appendix Table 7. Calibration Parameters**

Parameter	Scenario: 10% of the population infected	Source
Date range of simulation - START	1/3/2020	fitted
Date range of simulation - END	31/1/2021	assumed
Number of exposed people at start date	1	fitted
Probability of infection given contact (0 to 0.2)	0.029	fitted

**Appendix Table 8. Virus Parameters**

Relative infectiousness of incubation phase:	10%	Assumed value
Average incubation period:	3.5 d	Linton, N.M., et al., <i>Incubation Period and Other Epidemiologic Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data</i> . J Clin Med, 2020. 9(2). Khalili, M., et al., <i>Epidemiologic Characteristics of COVID-19; a Systematic Review and Meta-Analysis</i> . Plos One, 2020. Submitted. Bi, Q., et al <i>Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts</i> . medRxiv, 2020: p. 2020.03.03.20028423. <i>Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – seventh update</i> . Available from: <a href="https://www.ecdc.europa.eu/sites/default/files/documents/RRA-seventh-update-Outbreak-of-coronavirus-disease-COVID-19.pdf">https://www.ecdc.europa.eu/sites/default/files/documents/RRA-seventh-update-Outbreak-of-coronavirus-disease-COVID-19.pdf</a> .
Average duration of symptomatic infection period:	4.5 d	Linton, N.M., et al., <i>Incubation Period and Other Epidemiologic Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data</i> . J Clin Med, 2020. 9(2).
Probability upon infection of developing clinical symptoms:	55%	Mizumoto, K., et al., <i>Estimating the Asymptomatic Proportion of 2019 Novel Coronavirus onboard the Princess Cruises Ship, 2020</i> . medRxiv, 2020: p. 2020.02.20.20025866. Day, M., <i>Covid-19: four fifths of cases are asymptomatic, China figures indicate</i> . BMJ, 2020. 369: p. m1375. <i>Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – seventh update</i> . Available from: <a href="https://www.ecdc.europa.eu/sites/default/files/documents/RRA-seventh-update-Outbreak-of-coronavirus-disease-COVID-19.pdf">https://www.ecdc.europa.eu/sites/default/files/documents/RRA-seventh-update-Outbreak-of-coronavirus-disease-COVID-19.pdf</a> .
Probability upon hospitalization of requiring ICU admission with mechanical ventilation:	10%	Jordan MoH

**Appendix Table 9. Hospitalization Parameters**

Inputs	Value(s)	Input Source
Maximum number of hospital beds	3894 beds	Jordan MoH
Maximum number of ICU beds with ventilators	834 ventilators	Jordan MoH
Relative percentage of regular daily contacts when hospitalized:	15%	Assumed value
Probability of dying when hospitalized:	35%	<a href="https://www1.nyc.gov/site/doh/covid/covid-19-data.page">https://www1.nyc.gov/site/doh/covid/covid-19-data.page</a> . Zhou, F., et al., <i>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</i> . Lancet, 2020. 395(10229): p. 1054–1062.
Probability of dying when denied hospitalization:	50%	Petrilli, C.M., et al., <i>Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City</i> . medRxiv, 2020: p. 2020.04.08.20057794.
Probability of dying when admitted to ICU:	68%	value was recalculated from: Petrilli, C.M., et al., <i>Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City</i> . medRxiv, 2020: p. 2020.04.08.20057794. Lewnard, J.A., et al., <i>Incidence, clinical outcomes, and transmission dynamics of hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in California and Washington, United States: a prospective cohort study</i> . medRxiv, 2020: p. 2020.04.12.20062943. To reflect the hospital system in Jordan

Inputs	Value(s)	Input Source
Probability of dying when admission to ICU denied:	85%	value was recalculated from: Petrilli, C.M., et al., <i>Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City</i> . medRxiv, 2020: p. 2020.04.08.20057794. To reflect the hospital system in Jordan
Duration of hospitalized infection:	7 d	Jordan MoH
Duration of ICU with ventilation infection:	14 d	Jordan MoH

**Appendix Table 10.** Public health and social measures parameters

Self-isolation if Symptomatic	Parameter	Value	Source
	Adherence:	65%	Jordan MoH
(*Self-isolation) Screening			Jordan MoH
	Overdispersion: (1, 2, 3, 4 or 5)	4	Jordan MoH
	Test Sensitivity:	80%	Jordan MoH
(*Self-isolation) Household Isolation			
	Days in isolation for average person:	14 d	Jordan MoH
	Days to implement maximum quarantine coverage: (1 to 5)	2 d	Jordan MoH
	Decrease in the number of other contacts when quarantined:	20%	Jordan MoH
	Increase in the number of contacts at home when quarantined:	100%	Jordan MoH
Social Distancing			
	Adherence:	Varied %	Jordan MoH
Handwashing			
	Efficacy: (0%–25%)	5%	Jordan MoH
Mask Wearing			
	Efficacy: (0%–35%)	35%	Jordan MoH
Working at Home			
	Efficacy:	95%	Jordan MoH
	Home contacts inflation due to working from home:	10%	Jordan MoH
School Closures			
	Home contacts inflation due to school closure:	10%	Jordan MoH

**Appendix Table 11. Interventions**

Intervention	Date Start	Date End	Value	Unit	Source
Self-isolation if Symptomatic	3/16/2020	9/20/2020	85	%	Jordan MoH
Self-isolation if Symptomatic	9/21/2020	1/31/2021	50	%	Jordan MoH
Social Distancing	3/15/2020	5/1/2020	70	%	Jordan MoH
Social Distancing	5/2/2020	6/1/2020	45	%	Jordan MoH
Social Distancing	6/2/2020	7/1/2020	15	%	Jordan MoH
Social Distancing	7/2/2020	9/15/2020	10	%	Jordan MoH
Social Distancing	9/16/2020	9/25/2020	15	%	Jordan MoH
Social Distancing	9/26/2020	10/29/2020	35	%	Jordan MoH
Social Distancing	10/30/2020	10/31/2020	80	%	Jordan MoH
Social Distancing	11/1/2020	11/5/2020	50	%	Jordan MoH
Social Distancing	11/6/2020	11/7/2020	80	%	Jordan MoH
Social Distancing	11/8/2020	11/12/2020	50	%	Jordan MoH
Social Distancing	11/13/2020	11/14/2020	80	%	Jordan MoH
Social Distancing	11/15/2020	11/19/2020	50	%	Jordan MoH
Social Distancing	11/20/2020	11/21/2020	80	%	Jordan MoH
Social Distancing	11/22/2020	11/26/2020	50	%	Jordan MoH
Social Distancing	11/27/2020	11/28/2020	80	%	Jordan MoH
Social Distancing	11/29/2020	12/3/2020	50	%	Jordan MoH
Social Distancing	12/4/2020	12/5/2020	80	%	Jordan MoH
Social Distancing	12/6/2020	12/10/2020	50	%	Jordan MoH
Social Distancing	12/11/2020	12/12/2020	80	%	Jordan MoH
Social Distancing	12/13/2020	12/17/2020	50	%	Jordan MoH
Social Distancing	12/18/2020	12/19/2020	80	%	Jordan MoH
Social Distancing	12/20/2020	12/24/2020	50	%	Jordan MoH
Social Distancing	12/25/2020	12/26/2020	80	%	Jordan MoH
Social Distancing	12/27/2020	12/31/2020	50	%	Jordan MoH
Social Distancing	1/1/2021	1/2/2021	80	%	Jordan MoH
Social Distancing	1/3/2021	1/7/2021	50	%	Jordan MoH
Social Distancing	1/8/2021	1/9/2021	80	%	Jordan MoH
Social Distancing	1/10/2021	1/14/2021	50	%	Jordan MoH
Social Distancing	1/15/2021	1/16/2021	80	%	Jordan MoH
Social Distancing	1/17/2021	1/21/2021	50	%	Jordan MoH
Social Distancing	1/22/2021	1/23/2021	80	%	Jordan MoH
Social Distancing	1/24/2021	1/28/2021	50	%	Jordan MoH
Social Distancing	1/29/2021	1/30/2021	80	%	Jordan MoH
Social Distancing	1/31/2021	2/4/2021	50	%	Jordan MoH
Social Distancing	2/5/2021	2/6/2021	80	%	Jordan MoH
Social Distancing	2/7/2021	2/11/2021	50	%	Jordan MoH
Social Distancing	2/12/2021	2/13/2021	80	%	Jordan MoH
Social Distancing	2/14/2021	1/31/2021	50	%	Jordan MoH
Handwashing	2/25/2020	2/15/2021	100	%	Jordan MoH
Working at Home	3/17/2020	5/1/2020	70	%	Jordan MoH
Working at Home	5/2/2020	6/1/2020	45	%	Jordan MoH
Working at Home	6/2/2020	9/25/2020	15	%	Jordan MoH
Working at Home	9/26/2020	1/31/2021	35	%	Jordan MoH
School Closures	3/14/2020	9/1/2020	100	%	Jordan MoH
School Closures	9/15/2020	10/5/2020	70	%	Jordan MoH
School Closures	10/6/2020	1/31/2021	100	%	Jordan MoH